Source BioScience reports strong Q3

Diagnostics and genetic analysis business Source BioScience said a good performance in the third quarter meant it was on track to meet full year expectations.

The company said the three months to the end of September had been a period of sustained growth and

Article continues below

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

The performance was underpinned by growth in the firm's cytology business (which studies cell structure), driven by the adoption of automated imaging for cervical cancer screening.

The LifeSciences division also took increasing market share for DNA sequencing in the UK.

Source said it was in a robust financial position with £2m cash as of September 30th, up from £1.8m at the end of June.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.